📊 CTXR Key Takeaways
Is Citius Pharmaceuticals, Inc. (CTXR) a Good Investment?
Citius Pharmaceuticals faces an acute liquidity crisis with a current ratio of 0.58x and only $4.6M cash while burning $14.3M annually in operating losses. The company generates virtually no revenue growth ($5.6M flat YoY) against catastrophic operating expenses, creating an unsustainable business model. While the 80.1% gross margin suggests viable product economics, the company cannot survive 12 months at current cash burn without immediate capital injection or operational transformation.
Citius Pharmaceuticals shows extremely weak operating fundamentals: revenue is essentially flat at a very small base, while operating and net margins remain deeply negative and free cash flow burn is severe. Although leverage is low and the balance sheet is not debt-heavy, liquidity is tight and the company appears dependent on external capital or major business improvement to sustain operations.
Citius Pharmaceuticals, Inc. Key Strengths (CTXR)
- High gross margin of 80.1% indicates strong unit economics and pricing power if scaled
- Loss metrics improving year-over-year (net income +5.8%, diluted EPS +43.4%)
- Minimal debt burden ($600K) reduces financial leverage risk
- High gross margin indicates the existing revenue base is not structurally low-margin
- Very low long-term debt and debt-to-equity reduce balance sheet leverage risk
- Positive equity base provides some balance sheet support despite ongoing losses
CTXR Stock Risks: Citius Pharmaceuticals, Inc. Investment Risks
- Critical liquidity crisis: current ratio 0.58x with only $4.6M cash against $14.3M annual operating burn
- Zero revenue growth and massive -734.5% operating margin indicate fundamentally unviable business model at current scale
- Imminent shareholder dilution or insolvency - company cannot reach sustainable profitability without major transformation or external capital
- Operating losses remain far larger than revenue, with operating margin of -228.7%
- Weak liquidity profile with current ratio of 0.99x and quick ratio of 0.40x
- Negative operating cash flow and free cash flow suggest continued funding pressure if results do not improve
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Quarterly revenue growth and path to profitability timeline
- Operating expense reduction or revenue acceleration needed to achieve positive cash flow
- Quarterly operating cash burn relative to cash balance
- Revenue growth and operating margin improvement
Citius Pharmaceuticals, Inc. (CTXR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CTXR Profit Margin, ROE & Profitability Analysis
CTXR vs Healthcare Sector: How Citius Pharmaceuticals, Inc. Compares
How Citius Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Citius Pharmaceuticals, Inc. Stock Overvalued? CTXR Valuation Analysis 2026
Based on fundamental analysis, Citius Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Citius Pharmaceuticals, Inc. Balance Sheet: CTXR Debt, Cash & Liquidity
CTXR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Citius Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-5.97 indicates the company is currently unprofitable.
CTXR Revenue Growth, EPS Growth & YoY Performance
CTXR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $1.7M | -$9.4M | $-0.95 |
| Q1 2026 | $3.9M | -$9.4M | $-0.38 |
| Q3 2022 | $90.0K | -$4.1M | $-0.05 |
| Q2 2022 | $90.0K | -$4.1M | N/A |
| Q1 2022 | $90.0K | -$8.1M | N/A |
| Q3 2021 | $90.0K | -$4.1M | N/A |
| Q2 2021 | $90.0K | -$4.1M | N/A |
| Q1 2021 | $90.0K | -$4.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Citius Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
CTXR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Citius Pharmaceuticals, Inc. (CIK: 0001506251)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTXR
What is the AI rating for CTXR?
Citius Pharmaceuticals, Inc. (CTXR) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTXR's key strengths?
Claude: High gross margin of 80.1% indicates strong unit economics and pricing power if scaled. Loss metrics improving year-over-year (net income +5.8%, diluted EPS +43.4%). ChatGPT: High gross margin indicates the existing revenue base is not structurally low-margin. Very low long-term debt and debt-to-equity reduce balance sheet leverage risk.
What are the risks of investing in CTXR?
Claude: Critical liquidity crisis: current ratio 0.58x with only $4.6M cash against $14.3M annual operating burn. Zero revenue growth and massive -734.5% operating margin indicate fundamentally unviable business model at current scale. ChatGPT: Operating losses remain far larger than revenue, with operating margin of -228.7%. Weak liquidity profile with current ratio of 0.99x and quick ratio of 0.40x.
What is CTXR's revenue and growth?
Citius Pharmaceuticals, Inc. reported revenue of $5.6M.
Does CTXR pay dividends?
Citius Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find CTXR SEC filings?
Official SEC filings for Citius Pharmaceuticals, Inc. (CIK: 0001506251) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTXR's EPS?
Citius Pharmaceuticals, Inc. has a diluted EPS of $-1.34.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CTXR's fundamental grade?
Based on our AI fundamental analysis in June 2026, Citius Pharmaceuticals, Inc. has a D grade with 86% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CTXR stock overvalued or undervalued?
Valuation metrics for CTXR: ROE of -47.9% (sector avg: 15%), net margin of -524.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CTXR's AI grade for 2026?
Our dual AI analysis gives Citius Pharmaceuticals, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CTXR's free cash flow?
Citius Pharmaceuticals, Inc.'s operating cash flow is $-14.3M, with capital expenditures of $6.9K. FCF margin is -255.1%.
How does CTXR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -524.9% (avg: 12%), ROE -47.9% (avg: 15%), current ratio 0.58 (avg: 2).